NASDAQ · Biotechnology

BeyondSpring Inc. (BYSI) Stock

$1.17 +4.46% NASDAQ: BYSI Healthcare

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments.

Valuation

MetricValue
Price$1.17
Market Cap$48.11M
P/E Ratio-5.90
P/B Ratio-1.34
P/S Ratio0.00
EPS (TTM)$-0.20
52-Week High$2.44
52-Week Low$0.99
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE23.76%
ROA-41.52%
ROCE-141.93%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-0.01
Current Ratio1.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$1.0M$0$0$0
Operating Profit$-66.0M$-37.0M$-15.0M$-9.0M$-9.0M
Net Profit$-64.0M$-33.0M$-21.0M$-11.0M$-8.0M
EPS$-1.64$-0.85$-0.54$-0.28$-0.20
Op Margin-4903.0%-2756.4%———

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$82.0M$46.0M$25.0M$34.0M$26.0M
Total Liabilities$61.0M$49.0M$48.0M$49.0M$50.0M
Cash$42.0M$34.0M$15.0M$3.0M$8.0M
Borrowings$4.0M$5.0M$1.0M$1.0M$0

Latest News

BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value GlobeNewswire · Jun 4, 2026 BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026 GlobeNewswire · Jun 2, 2026 BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting GlobeNewswire · May 18, 2026 BeyondSpring shares rise after narrower quarterly loss and pipeline advances (BYSI) InvestorsHub · May 13, 2026 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Benzinga · May 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-47.0M$-28.0M$-16.0M$-16.0M$-20.0M
Investing Cash Flow$-23.0M$18.0M$0$-12.0M$13.0M
Financing Cash Flow$0$5.0M$0$23.0M$0
Net Cash Flow$-68.0M$-7.0M$-17.0M$-2.0M$5.0M
Free Cash Flow$-50.0M$-28.0M$-17.0M$-17.0M$-20.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.22
EV / EBITDA-5.53
FCF Yield-41.57%
Quick Ratio1.50
Interest Coverage0.00
Return 1Y-43.72%
Return 3Y16.07%
Return 5Y-86.87%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALXO $1.95 -2.26% -1.04 $261.72M 0.00%
ATYR $0.49 +1.19% -0.72 $47.62M 0.00%
BMEA $1.22 +0.00% -1.20 $88.21M 0.00%
CAMP $3.47 +6.12% -1.70 $73.70M 0.00%
DTIL $7.00 +1.60% -1.97 $89.80M 0.00%

About BeyondSpring Inc.

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.

BeyondSpring Inc. is led by CEO Lan Huang, employs 40 people, headquartered in US, publicly traded since 2017.

BeyondSpring Inc. (BYSI) stock trades at $1.17 with a market capitalization of $48.11M. The stock is valued at a price-to-earnings (P/E) ratio of -5.90, price-to-book of -1.34, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.99 and $2.44, and currently trades 52.0% below its 52-week high.

On profitability, BeyondSpring Inc. generates a return on equity (ROE) of 23.76% — well above the market average, a sign of a high-quality business, return on capital employed of -141.93%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.beyondspringpharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides